Fill-Finish Pharmaceutical Contract Manufacturing Global Market Report 2024

The fill-finish pharmaceutical contract manufacturing market size has grown strongly in recent years. It will grow from $10.96 billion in 2023 to $11.97 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historical period can be attributed to the rising demand for biologics, outsourcing trends, the globalization of pharmaceutical supply chains, an emphasis on quality assurance, and cost containment measures.

The fill-finish pharmaceutical contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $17.1 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to emerging market opportunities, pandemic preparedness, digital transformation, sustainability, and green initiatives, along with the expansion of personalized medicine. Major trends in the forecast period encompass flexible manufacturing solutions, partnerships, and collaborations, regulatory compliance, and serialization. Additionally, there is a focus on sustainability and green practices, as well as the integration of automation and robotics.

The anticipated growth in the fill-finish pharmaceutical contract manufacturing market is driven by the increasing demand for pharmaceutical products. Pharmaceutical products encompass medications or drugs formulated to diagnose, prevent, treat, or cure diseases in humans or animals. Fill-finish pharmaceutical contract manufacturing plays a vital role in aseptically filling injectables, biologics, and other pharmaceutical products. This service ensures precision, regulatory compliance, and streamlined manufacturing processes, maintaining high-quality products. For example, in June 2022, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the total pharmaceutical production in Europe reached $351 billion (€300,000 million) in 2021, reflecting a 5% increase from $335.2 billion (€286,697 million) in 2020. R&D investment in the Spanish pharmaceutical sector also rose by 9.2% to 1,267 million euros in 2021 compared to the previous year. Consequently, the growing demand for pharmaceutical products propels the fill-finish pharmaceutical contract manufacturing market's growth.

The increasing drug development pipeline is poised to drive the fill-finish pharmaceutical contract manufacturing market. The drug development pipeline outlines the comprehensive process a new pharmaceutical or therapeutic product undergoes, from initial discovery to market availability. In this pipeline, fill-finish pharmaceutical contract manufacturing is outsourced for the final stages of drug production, involving sterilization, filling into vials or syringes, sealing, and labeling. According to Qingdao ECHEMI Digital Technology Co Ltd. data from November 2021, the global research and development pipeline witnessed a 22.4% increase in anti-infective drugs in 2021 compared to the previous year. Additionally, the oncology drugs in the research and development pipeline totaled 6,961 drugs in 2021, indicating a 7.0% rise from 2020. Hence, the expanding drug development pipeline contributes to the growth of the fill-finish pharmaceutical contract manufacturing market.


Technological advancements emerge as a prominent trend in the fill-finish pharmaceutical contract manufacturing market. Companies within this sector are embracing innovative technologies to elevate product quality and adhere to stringent regulatory standards, ensuring their competitive position. For example, Steriline s.r.l., an Italy-based provider specializing in aseptic solutions, introduced robotic technologies tailored for small-batch aseptic filling in January 2023. These robotic systems enhance safety and flexibility in producing both toxic and non-toxic pharmaceutical drugs, minimizing the risk of human error, improving product quality, and optimizing operational efficiency.

Leading companies in the fill-finish pharmaceutical contract manufacturing market prioritize the integration of cutting-edge capabilities such as lyophilization technologies. Lyophilization capabilities involve a facility's expertise in the lyophilization process, or freeze-drying, which is crucial for drying and preserving biological or pharmaceutical products by removing water content through sublimation. In February 2022, Recro Pharma, Inc., a US-based contract development and manufacturing organization (CDMO), introduced Lyophilization Aseptic Fill/Finish to its range of services. This suite includes a sterile, automated vial filling system capable of filling up to 2,000 pre-sterilized vials per hour across various volumes. The equipment can lyophilize approximately 9,000 10 mL vials in each freeze-drying cycle, typically spanning 3-5 days.

In October 2021, PCI Pharma Services (PCI), a US-based provider of outsourced pharmaceutical services, acquired Lyophilization Services of New England Inc. (LSNE) for $1.5 billion. This strategic move expands PCI's capabilities in sterile injectables, lyophilization, and specialized formulation development and manufacturing. LSNE, a US-based contract development and manufacturing organization (CDMO), specializes in lyophilization, sterile fill-finish, and formulation development for pharmaceutical and biotechnology companies. The acquisition aligns LSNE's expertise with PCI's commitment to delivering integrated solutions for pharmaceutical companies.

Major companies operating in the fill-finish pharmaceutical contract manufacturing market report are AbbVie Inc., Novartis AG, Thermo Fisher Scientific Inc., Fresenius Kabi, Abbott Laboratories, Eurofins Scientific SE, Lonza Group Ltd., Catalent Inc., Sun Pharmaceutical Industries Limited, West Pharmaceutical Services Inc., Patheon, Samsung Biologics Co.Ltd., WuXi Biologics, Piramal Pharma Solutions, Pfizer CentreOne, Recipharm AB, Emergent BioSolutions Inc., Boehringer Ingelheim BioXcellence, Corden Pharma GmbH, Aenova Group, Baxter BioPharma Solutions , FUJIFILM Diosynth Biotechnologies, AGC Biologics, Rentschler Biopharma SE, Recro Pharma Inc., Cobra Biologics Limited, Grand River Aseptic Manufacturing (GRAM), MabPlex International Ltd., Cerbios-Pharma SA, Symbiosis Pharmaceutical Services Limited.

North America was the largest region in the fill-finish pharmaceutical contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fill-finish pharmaceutical contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fill-finish pharmaceutical contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary product types in fill-finish pharmaceutical contract manufacturing include prefilled syringes, vials, cartridges, and other products. Prefilled syringes are pre-loaded with a specific dose of medication, ensuring precise dosing, sterility, and quality control through the aseptic fill-finish pharmaceutical contract manufacturing processes. This outsourcing approach is employed for both large molecules and small molecules, with biopharmaceutical companies and pharmaceutical companies serving as the key end-users.

The fill-finish pharmaceutical contract manufacturing research report is one of a series of new reports that provides fill-finish pharmaceutical contract manufacturing market statistics, including the fill-finish pharmaceutical contract manufacturing industry’s global market size, regional shares, competitors with a fill-finish pharmaceutical contract manufacturing market share, detailed fill-finish pharmaceutical contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the fill-finish pharmaceutical contract manufacturing industry. This fill-finish pharmaceutical contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fill-finish pharmaceutical contract manufacturing market includes revenues earned by entities by providing septic filling, packaging, labeling, and serialization services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.